Why the study?
Does celecoxib reduce cardiorenal events compared to ibuprofen or naproxen in arthritis patients?
Does celecoxib reduce cardiorenal events compared to ibuprofen or naproxen in arthritis patients?
In arthritis patients, celecoxib demonstrated fewer renal events and a more favorable cardiovascular safety profile compared to ibuprofen or naproxen.
Answers are grounded in this paper and cite their sources.
May support preferring celecoxib for cardiorenal safety in arthritis; hypothesis-generating from observational data and needs RCT confirmation.
In the current era, long-term NSAID use was associated with few cardiorenal events in arthritis patients. At the doses studied, celecoxib displayed fewer renal events and hence more favourable cardiovascular safety compared with ibuprofen or naproxen. These results have considerable clinical implications for practitioners managing individuals with chronic arthritis pain and high risk of impaired renal function and/or heart failure.Clinical Trial Registration: NCT00346216.
No takes yet. Share an insight, caveat, or question.
Obeid et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: